Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Strong clinical evidence demonstrating sustained weight loss and cardiometabolic benefits is boosting confidence among patients and healthcare providers
Occurrence of nausea, vomiting and diarrhoea reported as adverse events with GLP-1 receptor agonists
Furthermore, Tirzepatide, administered once weekly at 15 mg, proved to be more effective than Semaglutide, administered once weekly at 1 mg, in reducing HbA1c levels
The single-dose vial and single-dose pen forms of Zepbound are not included at this time
US$ 21.59
US$ 22.02
US$ 28.54
US$ 24.51
